Literature DB >> 22611760

Cell proliferation and apoptosis in prostate needle biopsies with adenocarcinoma Gleason score 6 or 7.

Antonio Lopez-Beltran1, Liang Cheng, Ana Blanca, Rodolfo Montironi.   

Abstract

OBJECTIVE: To analyze whether cell proliferation and apoptotic indexes in needle biopsies with prostate cancer Gleason 6 or 7 can identify more objectively Gleason score 6 or 7 in needle biopsy samples. STUDY
DESIGN: Seventy patients diagnosed by needle biopsy and treated by radical prostatectomy were included. Fifty cases were Gleason score 6 and 20 were Gleason 7. Twenty-two cases were organ-confined and 48 nonorgan-confined. Histologic sections from needle biopsies were stained for cell proliferation using the MIB 1 (Ki67) antibody and in situ end-labeling technique for apoptosis and recorded as the percentage of positive cells. Statistical analysis included Student's t-test, Pearson's test, and logistic regression analysis.
RESULTS: We found increased apoptotic and proliferation indexes from Gleason 6 to 7, and from organ-confined to non-organ-confined. Apoptotic index was not associated to stage or Gleason score. We identified an association between cell proliferation and Gleason score indicating that higher proliferation index is associated with a higher probability of presenting a Gleason score 7. There was no association between pathologic stage and cell proliferation.
CONCLUSION: Cell proliferation and apoptosis can distinguish a subset of aggressive lesions in needle biopsies with Gleason 6 or 7 prostate adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22611760

Source DB:  PubMed          Journal:  Anal Quant Cytol Histol        ISSN: 0884-6812            Impact factor:   0.302


  2 in total

1.  Lactate dehydrogenase 5 isoenzyme overexpression defines resistance of prostate cancer to radiotherapy.

Authors:  M I Koukourakis; A Giatromanolaki; M Panteliadou; S E Pouliliou; P S Chondrou; S Mavropoulou; E Sivridis
Journal:  Br J Cancer       Date:  2014-04-08       Impact factor: 7.640

2.  Quantifying the ki-67 heterogeneity profile in prostate cancer.

Authors:  Shane Mesko; Patrick Kupelian; D Jeffrey Demanes; Jaoti Huang; Pin-Chieh Wang; Mitchell Kamrava
Journal:  Prostate Cancer       Date:  2013-10-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.